EGFR/HER2/DHFR-IN-2

EGFR/HER2/DHFR-IN-2

• UNSPSC Description: EGFR/HER2/DHFR-IN-2 (Compound 4b) is an inhibitor of EGFR, HER2, and DHFR (IC50: 0.248, 0.156, 0.138 μM respectively). EGFR/HER2/DHFR-IN-2 has anticancer activities against a panel of cancer cells (IC50: 9.14, 7.33, 14.18, 24.87, 20.07, 6.16 μM for Hep G2, HeLa, HEp-2, HCT 116, PC-3, MCF7 cells). EGFR/HER2/DHFR-IN-2 reduce breast cancer tumor growth[1].
• Target Antigen: Dihydrofolate reductase (DHFR) ; EGFR
• Type: Reference compound
• Related Pathways: JAK/STAT Signaling;Metabolic Enzyme/Protease;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/egfr-her2-dhfr-in-2.html
• Solubility: 10 mM in DMSO
• Smiles: N#CC1=C(OCCC)N=C(C2=CC=C(C)C=C2)C=C1C3=CC=C(Br)C=C3
• Molecular Weight: 407.30
• References & Citations: [1]Hawas SS, et al. New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: Synthesis, anticancer evaluation, and molecular modeling studies. Bioorg Chem. 2023 Sep 21;141:106874.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported